A Phase 2 interventional study of Fecal Microbiota Transplantation by Stool capsules and Fecal Microbiota Transplantation by Intra-rectal enemas in Pediatric Ulcerative Colitis in Remission, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 3 sites in France. Open to participants aged 8 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 1 of them phase 3. Colitis, Ulcerative · Assistance Publique - Hôpitaux de Paris.
Among the 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris, this one is one of 3 that started in 2026, is one of 3 in phase 2, and was the 6th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →6 of the 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 17
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–50 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 8 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 26 is below the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 116 across the 6 interventional studies, 255 across the 4 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
1 of the studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300553Assistance Publique - Hôpitaux de ParisImpact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether FMT by frozen stool capsules in pediatric UC patients in remission after corticosteroid treatment, can modify their dysbiotic gut microbiota by increasing the richness of their microbiota at 6 months.
Ulcerative colitis (UC) is characterized by chronic inflammation of the colon of undetermined origin. Their incidence is increasing dramatically in the paediatric population.
Pediatric-onset inflammatory bowel disease (IBD) is characterized by a greater severity than adult IBD. Although great progress has been made in recent years, the pathogenesis of IBD is not fully elucidated. During UC, an imbalance in the composition of gut microbiota, called "dysbiosis", has been identified. This dysbiosis is notably characterized by an increased proportion of pro-inflammatory microorganisms and a decreased proportion of anti-inflammatory microorganisms. The current treatments used in IBD mainly target the immune system through immunosuppressants, and help to shorten flairs and prevent recurrences, but there is no curative treatment.
From a therapeutic point of view, the correction of this dysbiosis is thus an attractive approach. Until now, efficacy of microbiome-based therapies such as probiotics or antibiotics has been disappointing in IBD. Fecal microbiota transplantation (FMT) consists of the administration of fecal material from a donor into the intestinal tract of a recipient to change their microbiota composition and restore healthy conditions. FMT has been successfully used for many years for the treatment of Clostridioides difficile infection. Recent studies seem to show a benefit of FMT in UC.
The investigator's main hypothesis is that the replacement of a dysbiotic microbiota by a 'healthy' microbiota by FMT can modify the richness of UC patient's microbiota and has a positive impact on the disease course.
Once steroid-induced remission will be achieved, patients will be included and randomised to receive either FMT by frozen stool capsules or enemas. They will receive 3 doses at 0, 1 and 2 months. They will be followed for one year with stool samples collected every 3 months. Clinical and laboratory data will be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For girls of childbearing age:
Exclusion Criteria for patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool capsules
Drug: Fecal Microbiota Transplantation by Stool capsules
Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool enemas.
Drug: Fecal Microbiota Transplantation by Intra-rectal enemas
After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia. The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces).
Also known as: UC treatment
After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia. The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas.
Also known as: UC Treatment
Success of FMT with frozen stool capsules defined by an increase in the richness of the recipient's microbiota at 6 months.
Success of FMT is defined by an increase in the richness of the recipient's microbiota at 6 months. Microbiota richness will be evaluated by measuring the alpha diversity of the microbiota using Shannon index. The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the recipient microbiota at M0 and the recipient microbiota at M6.
Time frame: 6 months after the first Fecal Microbiota Transplantation (FMT)
Success of FMT with frozen stool capsules defined by an increase in the richness of the recipient's microbiota at 12 months
The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the recipient microbiota at M0 and the recipient microbiota at M12.
Time frame: 12 months after the first FMT
Success of FMT by stool enema defined by an increase in the richness of the recipient's microbiota at 6 and 12 months
The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the recipient microbiota at M0 and the recipient microbiota at M6 and M12
Time frame: 6 and 12 months after the first FMT
Success of FMT with frozen stool capsules on the change of recipient dysbiotic microbiota at 6 and 12 months
The success of the FMT will be defined by a Bray Curtis (BC) Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.
Time frame: 6 and 12 months after the first FMT
Success of FMT by enema on the change of recipient dysbiotic microbiota at 6 and 12 months
The success of the FMT will be defined by a Bray Curtis (BC) Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.
Time frame: 6 and 12 months after the first FMT
Success of FMT with frozen stool capsules on the richness and change of mucosal microbiota at 12 months
The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the mucosal recipient microbiota at M0 and the mucosal recipient microbiota at M12
Time frame: 12 months
Success of FMT by enema on the richness and change of mucosal microbiota at 12 months
The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the mucosal recipient microbiota at M0 and the mucosal recipient microbiota at M12
Time frame: 12 months
Success of FMT with frozen stool capsules on the change of mucosal recipient dysbiotic microbiota at 6 and 12 months
The success of the FMT will be defined by a Bray Curtis (BC) Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.
Time frame: 6 and 12 months after the first FMT
Success of FMT by enema on the change of mucosal recipient dysbiotic microbiota at 6 and 12 months
The success of the FMT will be defined by a Bray Curtis Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.
Time frame: 6 and 12 months after the first FMT
FMT with frozen stool capsules Feasibility
Number of capsules intake, facility of capsules intake, tolerance, intake duration
Time frame: At inclusion, 1 and 2 months after each FMT
FMT by enema Feasibility
Number of enemas, tolerance , enemas duration, difficulties related to the application of enemas
Time frame: At inclusion, 1 and 2 months after each FMT
Ulcerative colitis clinical relapse
Defined as a Pediatric Ulcerative Colitis Activity Index (PUCAI) \> 35, number of relapses during the follow-up, treatments received during the follow-up
Time frame: 6 and 12 months
Ulcerative colitis Endoscopic relapse
Defined as an Ulcerative Colitis Endoscopic Index of Severity (UCEIS) ≥ 2
Time frame: 12 months
Change of inflammatory blood markers from baseline to 12 months
CRP, VS, Leucocytes levels
Time frame: At inclusion, 6, 9 and 12 months
Change of faecal calprotectin from baseline to 12 months
Calprotectin level
Time frame: At inclusion, 6, 9 and 12 months
Change of patient's quality of life evaluated with IMPACT-3 questionnaire from inclusion until 12 months
IMPACT-3 questionnaire of 35 closed questions - scale ranging from 1 to 5 for all answers - higher score suggesting better quality of life
Time frame: At inclusion 2, 6, 9 and 12 months
Incidence of adverse events
Time frame: 26 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jul 2028, 24 months later.
Of 45 non-industry phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 24 months is below that.
Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →